Medicare Enrolled
Dr. Ashraf Raslan, M.D.
Student in an Organized Health Care Education/Training Program · Jersey City, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Raslan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Raslan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Raslan
Dr. Ashraf Raslan is a student in an organized health care education/training program specialist in Jersey City, NJ, with 14 years of NPI registration. Based on federal Medicare data, Dr. Raslan performed 96,523 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Raslan received a total of $4,242 from 22 pharmaceutical and/or device companies across 279 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Raslan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years of NPI registration
▲ Top 0% volume in NJ
$4,242 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗96,523
Medicare services
Top 0% in NJ for student in an organized health care education/training program
Not available
Unique patients (not deduplicated)
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Tocilizumab injection (Actemra) | 60,200 | $5 | $12 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
17,075 | $11 | $60 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
8,025 | $34 | $102 |
| Denosumab injection (Prolia/Xgeva) | 5,220 | $18 | $36 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
3,250 | $26 | $100 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
571 | $103 | $279 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
432 | $8 | $15 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
325 | $59 | $274 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
232 | $1 | $53 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
194 | $75 | $181 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
161 | $103 | $541 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
160 | $0 | $29 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
136 | $24 | $115 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
108 | $12 | $72 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
70 | $7 | $286 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
69 | $64 | $207 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
67 | $136 | $594 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
53 | $14 | $67 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
39 | $4 | $104 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
38 | $85 | $394 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
37 | $135 | $394 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
21 | $63 | $207 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
16 | $100 | $292 |
| New patient office visit, complex (60-74 min) | 12 | $142 | $745 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
12 | $152 | $717 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
30.0% high complexity
68.5% medium
1.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,242
Total received (2018-2024)
Avg $606/year across 7 years
Top 9% in NJ for student in an organized health care education/training program
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
22
Companies
279
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$907
2023
$447
2022
$1,131
2021
$908
2020
$482
2019
$252
2018
$116
Payments by company (2024)
Amgen Inc.
$304
ABBVIE INC.
$197
Novartis Pharmaceuticals Corporation
$110
Janssen Biotech, Inc.
$82
Lilly USA, LLC
$76
E.R. Squibb & Sons, L.L.C.
$50
UCB, Inc.
$36
PFIZER INC.
$18
Genentech USA, Inc.
$17
Johnson & Johnson Health Care Systems Inc.
$17
Top 3 companies account for 67.4% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$1,084
E.R. Squibb & Sons, L.L.C.
$743
ABBVIE INC.
$451
AbbVie Inc.
$383
UCB, Inc.
$309
PFIZER INC.
$204
Lilly USA, LLC
$167
GlaxoSmithKline, LLC.
$163
Genentech USA, Inc.
$144
Aurinia Pharma U.S., Inc.
$121
Novartis Pharmaceuticals Corporation
$110
Horizon Therapeutics plc
$96
Janssen Biotech, Inc.
$82
Sobi, Inc
$30
AstraZeneca Pharmaceuticals LP
$30
Organon LLC
$28
Hikma Pharmaceuticals USA
$28
Johnson & Johnson Health Care Systems Inc.
$17
Takeda Pharmaceuticals U.S.A., Inc.
$14
SOBI, INC
$14
GENZYME CORPORATION
$13
AbbVie, Inc.
$12
Top 3 companies account for 53.7% of all-time payments
Associated products mentioned in payments ›
Actemra · BENLYSTA · BOTOX · Bimzelx · COSENTYX · Cimzia · ENTYVIO · EVENITY · Enbrel · HADLIMA · HUMIRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · Mitigare · ORENCIA · Otezla · Prolia · RAYOS · RENFLEXIS · RINVOQ · Rinvoq · Rituxan · SKYRIZI · TALTZ · TAVNEOS · TREMFYA · XELJANZ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Student in an organized health care education/training programs in nearby ZIP areas
34,039
County median income
$90,032
Nearest hospital to ZIP centroid (approximate)
CAREPOINT HEALTH-CHRIST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Raslan is a mixed practice specialist, with above-average Medicare volume (top 0% in NJ).
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Raslan experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Raslan performed 60,200 tocilizumab injection (actemra) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Raslan receive payments from pharmaceutical companies?
Yes. Dr. Raslan received a total of $4,242 from 22 companies across 279 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Raslan's costs compare to other student in an organized health care education/training programs in Jersey City?
Dr. Raslan's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Raslan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Student In An Organized Health Care Education/training Programs in Jersey City
Browse student in an organized health care education/training programs in Jersey City ranked by procedure volume and transparency data.
Highest volume
Top Student In An Organized Health Care Education/training Programs in NJ
Student in an organized health care education/training programs ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Student In An Organized Health Care Education/training Programs in NJ
Which NJ student in an organized health care education/training programs receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology